ID   FR-M-119
AC   CVCL_C545
DR   cancercelllines; CVCL_C545
DR   Cosmic; 2163848
DR   ESTDAB; ESTDAB-161
DR   Wikidata; Q54835145
RX   PubMed=23851445;
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445).
ST   Source(s): ESTDAB=ESTDAB-161
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,13
ST   D3S1358: 16,18
ST   D5S818: 12
ST   D7S820: 9,10
ST   FGA: 22,25
ST   TH01: 9.3
ST   TPOX: 9,12
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 14
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//